Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

[3H]MRE 3008F20: A Novel Antagonist Radioligand for the Pharmacological and Biochemical Characterization of Human A3 Adenosine Receptors

Katia Varani, Stefania Merighi, Stefania Gessi, Karl-Norbert Klotz, Edward Leung, Pier Giovanni Baraldi, Barbara Cacciari, Romeo Romagnoli, Giampiero Spalluto and Pier Andrea Borea
Molecular Pharmacology May 2000, 57 (5) 968-975;
Katia Varani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Merighi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Gessi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl-Norbert Klotz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Giovanni Baraldi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Cacciari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romeo Romagnoli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giampiero Spalluto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Andrea Borea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The lack of a radiolabeled selective A3 adenosine receptor antagonist is a major drawback for an adequate characterization of this receptor subtype. This paper describes the pharmacological and biochemical characterization of the tritiated form of a new potent A3 adenosine receptor antagonist, the pyrazolo triazolo pyrimidine derivative [3H]5N-(4-methoxyphenylcarbamoyl)amino-8-propyl-2-(2-furyl)pyrazolo[4,3-e] -1,2,4- triazolo[1,5-c]pyrimidine ([3H]MRE 3008F20). [3H]MRE 3008F20 bound specifically to the human adenosine A3 receptor expressed in CHO cells (hA3CHO), and saturation analysis revealed a single high affinity binding site, KD = 0.80 ± 0.06 nM, with a Bmax = 300 ± 33 fmol/mg protein. This new ligand displayed high selectivity (1294-, 165-, and 2471-fold) in binding assay to human A3 versus A1, A2A, and A2B receptors, respectively, and binds to the rat A3 receptors with a Ki > 10 μM. The pharmacological profile of [3H]MRE 3008F20 binding to hA3CHO cells was evaluated using known adenosine receptor agonists and antagonists with a rank order of potency consistent with that typically found for interactions with the A3 adenosine receptors. In the adenylyl cyclase assay the same compounds exhibited a rank order of potency identical with that observed in binding experiments. Thermodynamic data indicated that [3H]MRE 3008F20 binding to hA3CHO is entropy- and enthalpy-driven in agreement with the typical behavior of other adenosine antagonists to A1 and A2A receptors. These results show that [3H]MRE 3008F20 is the first antagonist radioligand with high affinity and selectivity for the human A3 adenosine receptor and may be used to investigate the physiopathological role of A3 adenosine receptors.

Footnotes

  • Send reprint requests to: Prof. Dr. Pier Andrea Borea, Faculty of Medicine, University of Ferrara, Department of Clinical and Experimental Medicine, Pharmacology Unit, Via Fossato di Mortara 17-19, 44100 Ferrara, Italy. E-mail: bpa{at}dns.unife.it

  • Abbreviations:
    AB-MECA
    4-aminobenzyl-5′-N-methylcarboxamidoadenosine
    MRE 3008F20
    5-N-(4-methoxyphenylcarbamoyl)amino-8-propyl-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
    NECA
    5′-N-ethylcarboxamidoadenosine
    DPCPX
    1,3-dipropyl-8-cyclopentylxanthine
    SCH 58261
    5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
    R-PIA
    R(−)-N6-(2-phenylisopropyl)adenosine
    S-PIA
    S(−)-N6-(2-phenylisopropyl)adenosine
    CGS 21680
    2-[p-(2-carboxyethyl)phenetylamino]-5′-N-ethylcarboxamidoadenosine
    IB-MECA
    N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide
    CHO
    Chinese hamster ovary
    CGS 15943
    5-amino-9-chloro-2-(furyl)-1,2,4-triazolo[1,5-c]quinazoline
    XAC
    8-[4-[[[[(2-aminoethyl)amino]carbonyl]methyl]oxy]phenyl]-1,3-dipropylxanthine
    MPC-NECA
    N6-(4-methoxyphenylcarbamoyl)- adenosine-5′-N-ethyluronamide
    MPC-MECA
    N6-(4-methoxyphenylcarbamoyl)adenosine-5′-N-methyluronamide
    MRE 3010F20
    5-N-(3-chlorophenylcarbamoyl)amino-8-propyl-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
    hA3CHO
    human adenosine A3 receptor expressed in CHO cells
    • Received October 1, 1999.
    • Accepted January 10, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 57 (5)
Molecular Pharmacology
Vol. 57, Issue 5
1 May 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
[3H]MRE 3008F20: A Novel Antagonist Radioligand for the Pharmacological and Biochemical Characterization of Human A3 Adenosine Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

[3H]MRE 3008F20: A Novel Antagonist Radioligand for the Pharmacological and Biochemical Characterization of Human A3 Adenosine Receptors

Katia Varani, Stefania Merighi, Stefania Gessi, Karl-Norbert Klotz, Edward Leung, Pier Giovanni Baraldi, Barbara Cacciari, Romeo Romagnoli, Giampiero Spalluto and Pier Andrea Borea
Molecular Pharmacology May 1, 2000, 57 (5) 968-975;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

[3H]MRE 3008F20: A Novel Antagonist Radioligand for the Pharmacological and Biochemical Characterization of Human A3 Adenosine Receptors

Katia Varani, Stefania Merighi, Stefania Gessi, Karl-Norbert Klotz, Edward Leung, Pier Giovanni Baraldi, Barbara Cacciari, Romeo Romagnoli, Giampiero Spalluto and Pier Andrea Borea
Molecular Pharmacology May 1, 2000, 57 (5) 968-975;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics